Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

The FDA granted de novo authorization to the first artificial intelligence (AI) program to support breast cancer risk ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

A recent clinical trial highlights how a high-fiber plant-based diet can improve health markers and potentially delay the ...

“And you’re going to be treated at Memorial Sloan Kettering Cancer Center.” Jan Claire supported her young­er sister as she underwent chemo­therapy, surgery, and radiation to treat triple negative ...

A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits. Dr. Kevin Liou presented the results of ...

A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer (TNBC), ...

Conquer Cancer®, the ASCO Foundation, presented the 2025 Young Investigator Awards (YIAs) funded by Vaniam Group™ and Women ...

When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic ...